Literature DB >> 1086834

The Tokelau Island migrant study: prevalence of various conditions before migration.

J M Stanhope, I A Prior.   

Abstract

The Tokelau Island Migrant Study has shown no important differences between those who subsequently left their home islands to migrate to New Zealand and those who remained, in key anthropometric and biochemical variables already reported. This comparison is now extended to various common diseases and conditions, and again no major difference emerges. The Tokelauans are compared with other Polynesians and shown to have less diabetes, hypertension, effort pain, chronic bronchitis and varicose veins than New Zealand Maoris, while resembling some Cook Island groups. Changes in prevalences of some conditions following migration are postulated.

Entities:  

Mesh:

Year:  1976        PMID: 1086834     DOI: 10.1093/ije/5.3.259

Source DB:  PubMed          Journal:  Int J Epidemiol        ISSN: 0300-5771            Impact factor:   7.196


  4 in total

1.  Effects of migration on cancer incidence and resources for prevention and treatment in Florida.

Authors:  H V McCoy; P N Ritchey; C B McCoy
Journal:  Public Health Rep       Date:  1992 Jul-Aug       Impact factor: 2.792

2.  Hypertension and indicators of coronary heart disease in Wallis Polynesians: an urban-rural comparison.

Authors:  R Taylor; P Bennett; R Uili; M Joffres; R Germain; S Levy; P Zimmet
Journal:  Eur J Epidemiol       Date:  1987-09       Impact factor: 8.082

3.  The prevalence of diabetes mellitus and impaired glucose tolerance in Melanesians and part-Polynesians in rural New Caledonia and Ouvea (Loyalty Islands).

Authors:  P Zimmet; D Canteloube; B Genelle; G LeGonidec; P Couzigou; M Peghini; M Charpin; P Bennett; T Kuberski; N Kleiber; R Taylor
Journal:  Diabetologia       Date:  1982-11       Impact factor: 10.122

4.  Acculturation of Pacific mothers in New Zealand over time: findings from the Pacific Islands Families study.

Authors:  Philip J Schluter; El-Shadan Tautolo; Janis Paterson
Journal:  BMC Public Health       Date:  2011-05-12       Impact factor: 3.295

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.